Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 EBIT per Share is €-0.06 as of Dec. 2024. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 685 Medical Devices & Instruments companies, Bonyf NV ranks better than 51.68% on this metric.
Bonyf NV's EBIT per Share for the
six
months ended in Dec. 2024 was €-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06.
During the past 3 years, the average EBIT per Share Growth Rate was 10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bonyf NV's EBIT per Share or its related term are showing as below:
XPAR:MLBON'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 10.8 Med: 10.8 Max: 10.8
Current: 10.8
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Bonyf NV was 10.80% per year. The lowest was 10.80% per year. And the median was 10.80% per year.
XPAR:MLBON's 3-Year EBIT Growth Rate is ranked better than 51.68% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs XPAR:MLBON: 10.80
Bonyf NV's EBIT for the
six
months ended in Dec. 2024 was €-0.03 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bonyf NV EBIT per Share Related Terms
Bonyf NV EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bonyf NV's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV (XPAR:MLBON) has a EBIT per Share of €-0.06 as of Dec. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bonyf NV and its competitors. According to the industry distribution chart, Bonyf NV ranks #331 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 48.3%.
Is Bonyf NV's EBIT per Share too high?
Bonyf NV's current EBIT per Share is €-0.06. Based on the distribution chart, Bonyf NV ranks #331 out of 685 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #331 out of 685 companies for EBIT per Share. This puts Bonyf NV in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current EBIT per Share is €-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current EBIT per Share is €-0.06. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current EBIT per Share is €-0.06 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
EBIT per Share: €-0.06
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
